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Background:  In resource-poor  settings,  cold  chain  requirements  present  barriers  for  vaccine  delivery.
We  evaluated  the immunogenicity  and  safety  of tetanus  toxoid  (TT)  vaccine  in “Controlled  Temper-
ature  Chain”  (CTC;  up  to  40 ◦C for <30  days  before  administration),  compared  to  standard  cold  chain
(SCC;  2–8 ◦C).  Prior  to the  study, stability  parameters  of  TT–CTC  were  shown  to  meet  international
requirements.
Methods:  A  cluster  randomized,  non-inferiority  trial was  conducted  in  Moïssala  district,  Chad,  December
2012–March  2013.  Thirty-four  included  clusters  were  randomized  to  CTC  or SCC.  Women  aged 14–49
years,  eligible  for  TT  vaccination  and  with  a history  of  ≤1 TT  dose,  received  two  TT  doses  4  weeks  apart.
Participants  were  blinded  to allocation  strategy.  Tetanus  antibody  titers  were  measured  using  standard
ELISA  at inclusion  and  4  weeks  post-TT2.  Primary  outcome  measures  were  post-vaccination  seroconver-
sion  and  fold-increase  in geometric  mean  concentrations  (GMC).  Non-inferiority  was  by seroconversion
difference  (TTSCC − TTCTC) <5%  and  ratio  of  GMCs  (TTSCC/TTCTC) <1.5.  Adverse  events  were  monitored  at
health  centers  and at next  contact  with  participants.
Results: A  total  of 2128  women  (CTC = 1068;  SCC  = 1060)  were  recruited.  Primary  intention  to  vaccinate
analysis  included  1830  participants;  272  of  these  were  included  in  the seroconversion  analysis.  Serocon-
version  was  reached  by >95%  of  participants;  upper  95%CI  of the difference  was  5.6%.  Increases  in  GMC
were  over  4-fold;  upper  95%CI  of GMC  ratio  was  1.36  in  the adjusted  analysis.  Few  adverse  events  were
recorded.
◦Conclusions:  This  study demonstrates  the  immunogenicity  and  safety  of  TT in  CTC at  <40 C for  <30  days.
The  high  proportion  of  participants  protected  at baseline  results  in  a reduction  of power  to detect  a  5%
non-inferiority  margin.  However,  results  at a 10%  non-inferiority  margin,  the  comparable  GMC  increases
and vaccine’s  stability  demonstrated  in  the  preliminary  phase  indicate  that  CTC  can  be an alternative
strategy  for  TT delivery  in situations  where  cold  chain  cannot  be  maintained.
ublis© 2014  The  Authors.  P∗ Corresponding author. Tel.: +33 140 21 54 97.
E-mail address: aitana.juan@epicentre.msf.org (A. Juan-Giner).
ttp://dx.doi.org/10.1016/j.vaccine.2014.09.027
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Effective immunization with tetanus toxoid (TT) requires a cold
chain system to store and transport vaccines at 2–8 ◦C from manu-
facturer to beneﬁciaries. The maintenance of the cold chain ensures
quality of all types of vaccines. However, it can be an obstacle
to vaccine delivery, especially in resource-poor countries where
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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old chain infrastructure and electricity are not always available
1,2]. Several studies have shown the feasibility of using speciﬁc
accines under controlled temperature chain (CTC) [3–11], where
accines are maintained outside the standard 2–8 ◦C recommen-
ation for a deﬁned duration and temperature, depending on the
accine’s particular heat-stability proﬁle [12]. The possibility of
sing speciﬁc vaccines outside storage recommendations started
ith the introduction of vaccine vial monitors (VVM) [13,14]. A
VM is a small sticker attached to the vaccine vial that contains a
ime–temperature sensitive square and an outer circle. When the
quare reaches the color of the circle, it indicates potential degra-
ation and the vial should be discarded [15].
Immunization of women with TT is a central strategy of the
aternal and neonatal tetanus elimination (MNTE) initiative [16].
his initiative aims to achieve the elimination goal of <1 neonatal
etanus (NT) case per 1000 live births per year in all districts of each
ountry by end 2015. By December 2013, 25 countries [17] had not
eached the elimination goal and others may  be at risk of increased
T cases if efforts to maintain high TT coverage in women  of child-
earing age do not continue [16]. One of the pillars of the MNTE
nitiative is to conduct TT supplementary immunization activities
SIA) targeting women of reproductive age in high-risk areas [16].
elivering TT vaccine in CTC could remove one of the important
arriers to reaching underserved and marginalized populations
onsidered mostly affected by tetanus.
This study was designed to assess immunological non-
nferiority of TT kept in CTC compared to standard cold chain (SCC)
hen administered to women of childbearing age. Additionally,
he safety of TT kept in CTC was assessed. A non-inferiority design
as based on the expectation that CTC would help increase vacci-
ation coverage by facilitating activities. Allocation to CTC or SCC
as done at cluster level to avoid potential confusion and adminis-
ration errors if individual randomization were used, as well as to
eplicate actual implementation strategies.
. Materials and methods
.1. Study design
This study was a cluster randomized, non-inferiority ﬁeld trial
onducted in three health zones of Moïssala district, Chad between
ecember 2012 and March 2013. Clusters, corresponding to a
illage or group of neighboring villages with an estimated popula-
ion of 600–800 residents, were identiﬁed. Clusters were stratiﬁed
ccording to distance to health centers (≤ or >5 km)  and to infant
accination activities taking place at village level. Clusters were
ssigned to receive TT kept in CTC or SCC with equal probabil-
ty and by stratum (Stata, College Station, TX, USA). All women
ged 14–49 years residing in study clusters were invited to partic-
pate and were allocated to CTC or SCC according to the predeﬁned
andom allocation. While vaccinators and health personnel con-
ucting the study were aware of allocation group, village heads,
able 1
esults of potency, pH and ﬂocculation tests for vaccines kept in controlled temperature 
Batch CTC 
Potency IU/dose (95%CI) pH Flocculation (total Lf/m
018B2001A 95 (73–124)1 6.56 19.2 (21 min) 
018L1008B 222 (161–308)1 6.63 18.4 (19 min) 
018L1024D 135 (98–185)2 6.53 19.2 (20 min) 
ote: The variability of potency results is related to an in-vivo testing. All batches meet int
old  chain batches.
1st run, reference value ED50 = 118.
2nd run, reference value ED50 = 125.32 (2014) 6220–6226 6221
participants and laboratory personnel analyzing samples were
blinded to the allocation.
In this study, CTC vaccines were kept outside the cold chain,
at <40 ◦C, from district to participant level for a maximum of 30
days.
2.2. Objectives
The primary objective of the study was  to demonstrate the non-
inferiority of TT kept in CTC compared to that kept in SCC in terms
of seroconversion and increase in antibody titers. Non-inferiority
of CTC vaccine could be claimed if, one month after vaccination, the
difference (TTSCC − TTCTC) in percentage of participants reaching
seroconversion was <5% and the ratio of geometric mean anti-
tetanus antibody concentrations (GMCs) (TTSCC/TTCTC) was <1.5.
The study also evaluated adverse events (AEs) following admin-
istration of TT kept in CTC and SCC.
2.3. Vaccine
In May  2012, prior to the study, TT in 10 dose-vials (Serum
Institute of India Limited, Hyderabad, India) from three different
batches (018B2001A, 018L1008B and 018L1024D) were exposed to
CTC conditions in Moïssala district, Chad. This vaccine has a VVM
30, reaching discard point after 30 days at 37 ◦C. Following this, CTC
vaccines were kept inside vaccine carriers without ice-packs for 30
days and carried by teams during a mass vaccination campaign and
outreach activities. Teams were instructed to perform daily duties
normally. A maximum ambient temperature of 43.1 ◦C was  regis-
tered during this period. Exposure temperatures were monitored
using electronic temperature recorders (LogTag® TRID30-7). Expo-
sure temperatures in the three vaccine carriers used ranged from
24.6 ◦C to 40.1 ◦C (mean 31.2 ◦C; with 30 ≤ 35 ◦C for 50% of the time
and ≥35 ◦C for 14%. A VVM percentage-based color intensity scale
previously used [3,11], with 100% indicating discard point, showed
50% change in color suggesting that exposure to heat had not dam-
aged the product. Control vaccines remained in the refrigerator in
Moïssala district (4.8–13.2 ◦C, with 3% of the time >8 ◦C).
Exposed and control vaccines were tested for potency, pH, tox-
icity and adsorption following standard testing procedures [18–20]
at the Belgian Scientiﬁc Institute of Public Health (WIV-ISP) in
Brussels. The WIV-ISP is authorized to perform the required in-
vivo tests; care of the animals was  in accordance with institutional
guidelines. After exposure period, laboratory results showed that
vaccines still met  speciﬁcations required for use and were con-
sidered stable (Table 1). The same vaccine batches were used for
immunization of study participants.2.4. Participants
Eligible participants were women  14–49 years of age living in
the study area who  had received a maximum of one previous TT
chain (CTC) and standard cold chain (SCC).
SCC
l) Potency IU/dose (95%CI) pH Flocculation (total Lf/ml)
94 (71–124)1 6.50 15.2 (23 min)
147 (108–200)2 6.66 18.4 (24 min)
92 (63–131)2 6.59 15.2 (30 min)
ernational requirement. No statistical differences were observed between CTC and
6222 A. Juan-Giner et al. / Vaccine 32 (2014) 6220–6226
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ose as determined by vaccination history, who were eligible for
accination according to the national schedule and who  had no
ontraindications to TT vaccination. Exclusion criteria included pre-
ious vaccine allergic reactions, pregnancy within two  weeks to
erm, traveling before the end of the study and unwillingness to
articipate. The vaccination history questionnaire was based on
he Multiple Indicators Cluster Survey (MICS) TT questionnaire pre-
iously used in Chad [21]. Participants’ vaccination cards/records,
hen available, were used to conﬁrm participants’ vaccination his-
ory. The questionnaire was pre-tested and administered by trained
nterviewers in the local languages. Eligibility for the study was
ssessed by a study nurse.
.5. Intervention
Study teams performed three planned visits to the villages. On
he day of inclusion into the study, ﬁve drops of ﬁngertip blood from
ach participant were collected on ﬁlter paper (Protein SaverTM
ard, Whatman 903). After blood sampling, the vaccinator adminis-
ered the 1st dose of TT vaccine intramuscularly into the left deltoid
uscle. Four to six weeks later study teams returned to the villages
o administer the 2nd TT dose. After 4 weeks, when antibody con-
entrations are considered to peak [22], a third visit was  conducted
o obtain a second blood sample. Participants received two  TT doses
ept in CTC or SCC according to the strategy randomly assigned to
heir cluster.CTC vaccines were placed in vaccine carriers without ice-packs
or a maximum of 30 days. Number of days in CTC and VVM sta-
us were registered daily. Exposure temperatures were monitored
ontinuously using LogTag® TRID30-7.’ ﬂow chart.
Participants were observed for 30 min  after vaccination to
manage and record immediate AEs. AEs occurring 7 days post-
vaccination were evaluated at the next contact with study team
or at a local health center if participant sought medical assistance.
2.6. Outcomes
The main study outcomes were the proportion of participants
protected against tetanus and the fold-increase in antibody level
after two doses of TT vaccine. AEs were also analyzed.
Dried whole blood absorbed on ﬁlter paper was used to deter-
mine anti-tetanus antibodies. Samples were dried at ambient
temperatures for 4 h and placed in individual plastic bags with a
silica sachet. Samples were kept at ambient temperatures (<25 ◦C)
in an air-conditioned room. Once in the laboratory, samples were
kept at −15 to −25 ◦C for long-term storage.
Anti-tetanus IgG levels were determined using an indirect
endpoint ELISA test validated by the WIV-ISP: 30 l of standard
TT solution (PhEur. Biological Reference Preparation, 0.03 IU/ml)
and in-house positive control anti-tetanus antibody solution
(0.05 IU/ml) were spotted onto ﬁlter paper. Standardized discs
were punched using an ofﬁce paper puncher (Harris Uni-Core I.D.
6.0 mm)  from the center of the dried blood spots and from blank
paper discs used as negative controls. Standard, control and par-
ticipants’ discs were added in duplicate in a ﬂat-bottomed 96-well
microtiter plate (NUNC, TC microwell). The discs were eluted with
200 l of ELISA compatible buffer (PBS) and incubated for 90 min.
Eluted standard, controls and patient samples were diluted with
PBS buffer and loaded into TT-antigen pre-coated wells of an ELISA
plate (NUNC MaxiSorpTM). The incubation of standard, control and
ccine 32 (2014) 6220–6226 6223
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Table 2
Participants and clusters characteristics in the controlled temperature chain (CTC)
and  standard cold chain (SCC) groups*.
CTC SCC
Participants’ characteristics
Participants 1068 1060
Age (years) 25.25 (11.23) 24.97 (11.06)
Pregnant at inclusion 64 (5.97%) 79 (7.48%)
Number of pregnancies 2.69 (3.14) 2.55 (3.07)
Never been pregnant 392 (36.6%) 392 (37.1)
Years last pregnancy 4.65 (6.30) 4.27 (6.00)
Received a TT dose before
inclusion
530 (49.5%) 554 (52.4%)
Years last TT dose 5.23 (5.94) 4.94 (5.30)
Baseline GMC  in IU/ml (95%CI) 0.35 (0.33–0.36) 0.35 (0.33–0.37)
Clusters’ characteristics
Number of clusters 17 17
Participants per cluster (range) 63 (39–123) 62 (33–88)
Clusters >5 km from health
facility
10 (62.5%) 11 (64.7%)
Clusters with routine vaccination 5 (29.4%) 6 (35.3%)
T
E
1
2
3A. Juan-Giner et al. / Va
amples was followed by successive additions of biotynilated
abbit anti-hIgG (Thermo Fisher Scientiﬁc), streptavidine-
eroxidase and Tetramethylbenzidin (TMB). Optical density
as measured with the Softmax PRO software (Molecular Devices)
t 450 nm and 650 nm.  Anti-tetanus antibody concentrations were
uantiﬁed by comparison with the standard curve (4-parameter
tting).
.7. Sample size
The sample size was calculated based on anticipated serocon-
ersion frequency. We  assumed that after 2 TT doses kept at 2–8 ◦C
s recommended, 90% of participants would have a protective anti-
ody level. To detect a difference of not more than 5% in the CTC
roup compared to the cold chain group, with a one-sided  ˛ of 2.5%
nd 90% power, we aimed to enroll 1050 participants per group.
his considered a possible 10% loss to follow-up. Due to the small
eographical area of the study site, stratiﬁcation and randomiza-
ion, the intra-cluster correlation coefﬁcient was considered small
<0.005). The 5% non-inferiority margin was chosen based on both
tatistical and clinical considerations and was considered accept-
ble and conservative in terms of the public health relevance of CTC.
.8. Statistical methods
Immunological responses evaluated include seroconversion,
eroprotection and increase in GMC. As recommended by World
ealth Organization (WHO), an anti-tetanus IgG level of 0.16 IU/ml
as considered protective [22]. Because protective antibody is
verestimated by standard indirect ELISA at values <0.20 IU/ml
hen compared to neutralization assay [23,24], an additional anal-
sis was conducted using 0.20 IU/ml as the cutoff. For the analysis
f the increase in GMCs, pre- and post-vaccination antibody con-
entrations and their differences were log10-transformed to obtain
 more closely normal distribution. Differences in seroconversion
ercentages and increase in GMCs were analyzed using the upper
imit of the Wilson-type 95% conﬁdence interval (CI). Inverse cumu-
ative distribution curves were also compared.
An additional analysis of the ratio of GMCs was  computed using
nalysis of covariance to adjust for baseline characteristics and
luster. Differences between the groups regarding post-vaccination
eactions were analyzed using Fisher’s exact test. Immunogenicity
nalysis was conducted both for intention-to-vaccinate (ITV) and
er-protocol (PP) populations. Safety analysis included all study
articipants. Data were double entered by independent data clerks
nd analyzed with STATA software, version 11.2.
.9. Ethical considerationsThe study was designed and performed in accordance with the
rinciples of the Declaration of Helsinki and with Good Clinical
ractice Guidelines established by the International Conference
n Harmonization. The study was approved by the Committee
able 3
xposure temperatures in the controlled temperature chain (CTC) and standard cold chai
TT dose and strategy Temperatures 
Mean (◦C) Range (◦C) 
TT1–CTC 27.7 21.4–37.5 
TT2–CTC 29.0 21.9–38.3 
TT1–SCC 5.6 1.5–11.22
TT2–SCC 5.9 1.7–9.33
VVM read on a percentage scale with 100% indicating discard point.
>8 ◦C for 35 min  registered after opening the refrigerator for the provision of vaccines; <
>8 ◦C for 10 min  registered after opening the refrigerator for the provision of vaccines; <activities
* Data are means (SD) or numbers (%).
for the protection of persons in France (St. Germain en Laye)
and discussed at Chad’s National Vaccination Technical Commit-
tee before approval by the Ministry of Health in Chad. The head
of each participating village provided permission for their village
to participate and written informed consent was  obtained before
enrollment from all participants. All participation was voluntary
and no identifying information encoded. The trial was registered at
clinicaltrials.org with registry number NCT01559597.
3. Results
3.1. Study population
A total of 2128 participants residing in 42 villages grouped in
34 clusters were enrolled in this study (1068 in CTC; 1060 in SCC)
(Fig. 1). A total of 952 participants completed the study in each
group. The primary ITV analysis included 1830 participants with
pre- and post-vaccination antibody level results (913 in CTC; 917
in SCC). The PP population (n = 1563) includes all participants who
received 2 TT doses 21 to 42 days apart according to the allocated
strategy, had blood sampling 21 to 42 days post TT2 and had pre-
and post-vaccination serological results. The reasons for exclusion
from the PP analysis were an incorrect interval between TT doses
and/or blood sampling (n = 240) and receiving TT doses kept in dif-
ferent strategies (n = 27). Baseline demographics were similar in
both arms (Table 2).3.2. Administered vaccines
Administered CTC vaccines were exposed to temperatures
between 21.4 and 38.3 ◦C (25 ≤ 30 ◦C during 71.4% of time and
n (SCC) and vaccine vial monitor (VVM) status of administered vaccines.
Duration of CTC VVM (%)1
Median (days) Range (days)
16.0 5–27 40
14.0 7–26 40
– – 10
– – 10
2 ◦C registered in 3 vaccine carriers (from 20 used) during a maximum of 1.5 h.
2 ◦C registered in 1 vaccine carrier (from 34 used) during 1 h.
6 ccine 32 (2014) 6220–6226
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30 ◦C for 20%) for 5 to 27 days with a median of 16 and 14 days
or ﬁrst and second dose (Table 3). Cold chain vaccines were kept
etween 1.5 and 11.2 ◦C (<2 or >8 ◦C for 0.2% of the time). At the
ime of use, all VVMs indicated that vaccine could be used.
.3. Immunogenicity
At baseline, 272 participants (14.9%), had anti-tetanus IgG
evels of <0.16 IU/ml (142 in CTC; 130 in SCC). Among suscepti-
le participants, 95.77% (95%CI = 91.09–98.05) in CTC and 96.15%
95%CI = 91.31–98.35) in SCC had protective antibody levels follow-
ng two doses of TT (Table 4). The upper limit of the 95%CI for the
ifference in seroconversion was 5.6 in the ITV analysis and 4.4 in
he PP analysis. If a protection cutoff of 0.20 IU/ml is used, there
ere 512 susceptible participants at baseline (259 in CTC; 253 in
CC); the difference in seroconversion was 1.48 (95%CI = −2.8 to
.7).
Following vaccination, overall seroprotection was  equal in both
roups: 99.34% in the CTC and 99.45% in the SCC groups (Table 4).
Pre-vaccination GMC  was 0.35 IU/ml in both groups (p = 0.82).
fter vaccination, GMCs were 1.47 IU/ml (95%CI = 1.40–1.54) in the
TC group and 1.55 IU/ml (95%CI = 1.48–1.62) in the SCC. Inverse
umulative distribution curves of GMCs pre and post-vaccination
y group are presented in Fig. 2.
After vaccination, there was a 4.21-fold increase in GMC  in the
TC group (95%CI = 4.00–4.43) and a 4.51-fold (95%CI = 4.31–4.73)
n the SCC group. The upper limit of the 95%CI for the ratio
f GMCs was 1.16. The regression model adjusting for GMC  at
aseline and previous vaccination showed a GMCs ratio of 0.99
95%CI = 0.72–1.36). The PP analysis did not show any signiﬁcant
ifferences (Table 4).
.4. Safety
Almost all participants (97.3%) were observed for the full 30 min
fter vaccination. No AEs were observed during this period. A small
umber of participants (n = 25) self-reported AEs occurring 7 days
fter vaccination (2 in CTC, 23 in SCC, p < 0.000). These were char-
cterized by a local reaction at the injection site with pain and
welling accompanied by fever in 13 cases and headache in 8. No
Es were reported by health centers.
. Discussion
This study demonstrates the stability and immunogenicity of
T kept in CTC at temperatures <40 ◦C for up to 30 days. Laboratory
esults showed that TT in CTC retained adequate potency levels.
eroprotection results and cumulative distribution curves showed
imilar immunological responses in CTC and SCC groups. In this
tudy, the high proportion of participants already protected at base-
ine resulted in a reduction of power to detect the non-inferiority
n seroconversion in the CTC group at a 5% margin as intended.
owever, previous CTC studies have used 10% non-inferiority mar-
in [25]. In this study, a 10% margin with a protection threshold
f 0.20 IU/ml results in 96.3% power to establish non-inferiority of
T in CTC. Seroconversion results, comparable increases in GMC
nd vaccine’s stability demonstrated in the preliminary study phase
ndicate that TT in CTC does not result in a signiﬁcant loss of vaccine
ffectiveness.
The possibility of using TT in CTC is a major advantage for
ountries where maternal and neonatal tetanus continues to be public health problem. WHO  recommends immunization against
etanus with the combined tetanus and diphtheria toxoids [26].
owever, TT continues to be used in most countries aiming to
chieve MNTE goals [27]. The implementation of SIAs in CTC Ta
b
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B  using a novel pre-ﬁlled immunisation device stored outside the cold chain.ig. 2. Inverse cumulative distribution curves, pre- and post-vaccination GMCs in
he  controlled temperature chain (CTC) and standard cold chain (SCC) group.
resents an opportunity to reach populations that are inaccessible
y “traditional” strategies.
Registration of AEs occurring after vaccination relied on self-
eporting. Previous studies have shown that spontaneous reporting
f AE after TT administration is infrequent [28]. A larger number of
omen might have experienced reactions that were not reported;
here was no indication that any serious unreported AE occurred.
In this study, baseline tetanus protection was higher than
nticipated. It is possible that despite the use of a structured ques-
ionnaire by trained interviewers, not all previous TT doses were
aptured. TT vaccination history can be difﬁcult to determine, espe-
ially among women vaccinated a long time ago [29] and those with
ow awareness of the purpose of vaccination [30]. Nonetheless, we
ound that 74.5% of young (<21 years) nulliparous women  without
revious TT vaccination opportunities were protected at baseline
ccording to our ELISA technique and 0.16 IU/ml cut-off.
Antibody levels obtained from standard indirect ELISA over-
stimate protection at low antibody levels; use of that assay
ay  have limited the detection of participants with insufﬁcient
eutralizing anti-tetanus antibodies for protection. The use of a
odiﬁed ELISA technique, such as double-antigen or inhibition
LISA or toxin-binding inhibition assay (ToBI) would have provided
ntibody level results that correlate better with those obtained
ith in vivo neutralization assays [23]. The use of a 0.20 IU/ml
ut-off probably provides a more accurate assessment of the pro-
ection in the study population. Use of different assays and lack
f standardization between laboratories limit the comparison of
esults across studies. Agreement on an internationally recognized
ethodology would facilitate comparison and interpretation of
esults [22].32 (2014) 6220–6226 6225
In addition, in response to a meningitis epidemic, a campaign
using meningococcal serogroup A polysaccharide-TT conjugate
vaccine (PsA-TT) was conducted in the study area 7 months before
study initiation. 69.6% of participants reported receiving the vac-
cine. The anti-tetanus immunizing effect of PsA-TT [31] likely
contributed to the high baseline protection.
This study demonstrates that TT manufactured by Serum Insti-
tute of India Limited can be used in CTC in settings with high
ambient temperatures. The use of TT produced by other manu-
factures in CTC needs to be evaluated. To date the only vaccine
licensed for use in CTC is PsA-TT (MenAfriVac). The adoption of CTC
strategies requires political engagement that facilitates licensure
of vaccines in CTC by manufacturers and regulators and supports
its implementation by countries. The use of CTC can help increase
vaccination coverage by reaching people living in remote areas
and increasing availability of vaccines in places where cold chain
is extremely difﬁcult to maintain. It can also reduce logistical
demands and cost of SIAs [32]. These are major advantages for the
countries that are still striving to achieve MNTE.
Competing interest statement
The authors declare no competing interests.
Acknowledgements
We wish to thank the population of Ngalo, Biri and Kaba 6 for
their participation in the study. Many thanks also to health and
administrative authorities in Ngalo, Biri, Kaba 6, Moïssala, Man-
doul and N’Djamena for their support and engagement. We  are also
grateful to the Médecins Sans Frontières teams in the ﬁeld for their
hard work and enthusiasm in the conduct of the study. We  also
thank Médecins Sans Frontières headquarters staff involved in the
study for their support and advice. Thanks also to Serum Institute
of India Ltd for their advice and recommendations. Many thanks for
their huge work to all staff involved in the in vivo and in vitro assays
at the WIV-ISP, especially to Isabelle Hansenne, Fabrice Ribaucour
and Geneviève Waeterloos.
This study was  ﬁnanced by MSF  and the project Optimize,
a WHO-PATH collaboration funded by the Bill & Melinda Gates
Foundation.
This study was conceived by FF, RFG, SZ and AJG. All authors
provided substantial contributions to the design of the study. AJG,
PB, PG and MT  were involved in the study implementation. CL, CD
and MHR  were involved in the interpretation of the results. The ﬁrst
draft of the manuscript was  written by AJG and RFG. All authors
contributed to the writing of the manuscript and agree with the
results and conclusions.
References
[1] Humphreys G. Vaccination: rattling the supply chain. Bull World Health Organ
2011;89(5):324–5.
[2] Zaffran M,  Vandelaer J, Kristensen D, et al. The imperative for stronger vaccine
supply and logistics systems. Vaccine 2013;31(Suppl 2):B73–80.
[3] Halm A, Yalcouyé I, Kamissoko M,  et al. Using oral polio vaccine beyond the
cold  chain: a feasibility study conducted during the national immunization
campaign in Mali. Vaccine 2010;28(19):3467–72.
[4] Hipgrave DB, Tran TN, Huong VM,  et al. Immunogenicity of a locally produced
hepatitis B vaccine with the birth dose stored outside the cold chain in rural
Vietnam. Am J Trop Med  Hyg 2006;74(2):255–60.
[5] Kerdpanich A, Chokephaibulkit K, Watanaveeradej V, et al. Immunogenicity of
a  human rotavirus vaccine (RIX4414) after storage at 37 ◦C for seven days. Hum
Vaccine 2011;7(1):74–80.
[6] Otto BF, Suarnawa IM,  Stewart T, et al. At-birth immunisation against hepatitisVaccine 1999;18(5–6):498–502.
[7] Quiroga R, Halkyer P, Gil F, Nelson C, Kristensen D. A preﬁlled injection device
for  outreach tetanus immunization by Bolivian traditional birth attendants. Rev
Panam Salud Publica 1998;4(1):20–5.
6 ccine
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[226 A. Juan-Giner et al. / Va
[8] Ren Q, Xiong H, Li Y, Xu R, Zhu C. Evaluation of an outside-the-cold-chain vac-
cine delivery strategy in remote regions of western China. Public Health Rep
2009;124(5):745–50.
[9] Sutanto A, Suarnawa IM,  Nelson CM,  Stewart T, Soewarso TI. Home deliv-
ery of heat-stable vaccines in Indonesia: outreach immunization with a
preﬁlled, single-use injection device. Bull World Health Organ 1999;77(2):
119–26.
10] Wang L, Li J, Chen H, et al. Hepatitis B vaccination of newborn infants in rural
China: evaluation of a village-based, out-of-cold-chain delivery strategy. Bull
World Health Organ 2007;85(9):688–94.
11] Zipursky S, Boualam L, Cheikh DO, et al. Assessing the potency of oral polio vac-
cine kept outside of the cold chain during a national immunization campaign
in Chad. Vaccine 2011;29(34):5652–6.
12] McCarney S, Zaffran M.  Controlled temperature chain. The new term for out of
the cold chain. Ferney: PATH; 2009.
13] WHO. Temperature sensitivity of vaccines. In: WHO/IVB/06.10. Geneva: WHO;
2006.
14] WHO. Making use of vaccine vial monitors ﬂexible vaccine management for
polio. In: WHO/V&B/00.14. Geneva: WHO; 2000.
15] WHO. Vaccine vial monitor. PQS performance speciﬁcation. In:
WHO/PQS/E06/IN05.1. Geneva: WHO; 2006.
16] WHO–UNICEF–UNFPA. Achieving and sustaining maternal and neonatal
tetanus elimination. Strategic plan 2012–2015. Geneva: WHO–UNICEF–
UNFPA; 2012.
17] WHO. Maternal and neonatal tetanus (MNT) elimination. Progress towards
global MNT  elimination. Geneva: WHO; 2012. Available at 〈http://www.who.
int/immunization/diseases/MNTE initiative/en/index4.html〉.
18] WHO. Requirements for diphtheria, tetanus, pertussis and combined vac-
cines. In: Annex 2. Technical report series no. 800. Geneva: WHO;
1990.
19] WHO. Production and control of tetanus vaccine. A training curriculum. Mod-
ule IV. Microbiological and immunochemical tests. In: WHO/VSQ/GEN/94.5.
Geneva: WHO; 1994.
20] WHO. Recommendations to assure the quality, safety and efﬁcacy of tetanus
vaccines. In: Replacement of: TRS 800, Annex 2 and TRS 927, Annex 5. Geneva:
WHO; 2012.
[ 32 (2014) 6220–6226
21] UNICEF. Designing the questionnaire. In: Monitoring progress toward the goals
of  the world summit for children. A practical handbook for multiple-indicator
surveys. UNICEF; 1995 (Chapter 3).
22] Borrow R, Balmer P, Roper M.  The immunological basis for immunization series
Module 3: tetanus update 2006. Geneva: WHO  Department of Immunization,
Vaccines and Biologicals; 2007.
23] Simonsen O, Schou CHI. Modiﬁcation of the ELISA for the estimation of tetanus
antitoxin in human sera. J Biol Stand 1987;15:143–57.
24] Dokmetjian J, Della Valle C, Lavigne V, de Luján CM,  Manghi Ma.  A possible
explanation for the discrepancy between ELISA and neutralising antibodies to
tetanus toxin. Vaccine 2000;18(24):2698–703.
25] Schöndorf I, Banzhoff A, Nicolay U, Diaz-Mitoma F. Overcoming the need for
a  cold chain with conjugated meningococcal group C vaccine: a controlled,
randomized, double-blind study in toddlers on the safety and immuno-
genicity of Menjugate, stored at room temperature for 6 months. Vaccine
2007;25(7):1175–82.
26] WHO. Tetanus vaccine. WHO  position paper. Wkly Epidemiol Rec Relev
2006;81(20):198–208.
27] WHO. Vaccine preventable diseases: monitoring system July 2014
global summary. Geneva: WHO; 2014. Available at 〈http://apps.who.int/
immunization monitoring/globalsummary〉.
28] Lloyd JC, Haber P, Mootrey GT, Braun MM,  Rhodes PH, Chen RT. Adverse event
reporting rates following tetanus–diphtheria and tetanus toxoid vaccinations:
data from the vaccine adverse event reporting system (VAERS), 1991–1997.
Vaccine 2003;21(25–26):3746–50.
29] Deming MS,  Roungou J-B, Kristiansen M,  et al. Tetanus toxoid coverage as an
indicator of serological protection against neonatal tetanus. Bull World Health
Organ 2002;80(9):696–703.
30] Kurtzhals JAL, Kjeldsen K, Hey AS, O-odera EAO. Immunity to tetanus and diph-
theria in rural Africa. Am J Trop Med  Hyg 1997;56(5):576–9.
31] Kshirsagar N, Mur  N, Thatte U, et al. Safety, immunogenicity, and antibody per-
sistence of a new meningococcal group A conjugate vaccine in healthy Indian
adults. Vaccine 2007;25(Suppl 1):A101–7.
32] Lydon P, Zipursky S, Tevi-Benissan C, et al. Economic beneﬁts of keeping vac-
cines at ambient temperature during mass vaccination: the case of meningitis
A  vaccine in Chad. Bull World Health Organ 2014;92(2):86–92.
